CNCR logo

CNCR Overview

Profile

Name:

Range Cancer Therapeutics Index ETF

Assets under management:

$13 M

Expense ratio:

0.79%

Inception date:

October 14, 2015

Website:

-

Last ex-dividend date:

December 29, 2021

Next ex-dividend date:

N/A

Description:

The CNCR ETF is an exchange-traded fund that focuses on companies involved in cancer research and treatment. It aims to provide investors with exposure to the growing healthcare sector, particularly in oncology, by investing in firms developing innovative therapies and technologies for cancer care.

Top holdings

Name
Weight
3.59 %
REPL logo
Replimune(REPL)
3.54 %
ZYME logo
Zymeworks(ZYME)
3.45 %
ARGX logo
argenx SE(ARGX)
3.42 %
3.42 %
3.39 %
XNCR logo
Xencor(XNCR)
3.37 %
3.37 %
3.33 %
3.33 %
3.32 %
Trillium Therapeutics Inc.(TRIL)
3.29 %
Rubius Therapeutics, Inc.(RUBY)
3.29 %
3.28 %
3.28 %
IMAB logo
I-Mab(IMAB)
3.25 %
3.23 %
3.23 %
3.20 %
BGNE logo
BeiGene(BGNE)
3.19 %
3.17 %

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Technical Analysis

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend per share

Top holdings

Name
Weight
3.59 %
REPL logo
Replimune(REPL)
3.54 %
ZYME logo
Zymeworks(ZYME)
3.45 %
ARGX logo
argenx SE(ARGX)
3.42 %
3.42 %
3.39 %
XNCR logo
Xencor(XNCR)
3.37 %
3.37 %
3.33 %
3.33 %
3.32 %
Trillium Therapeutics Inc.(TRIL)
3.29 %
Rubius Therapeutics, Inc.(RUBY)
3.29 %
3.28 %
3.28 %
IMAB logo
I-Mab(IMAB)
3.25 %
3.23 %
3.23 %
3.20 %
BGNE logo
BeiGene(BGNE)
3.19 %
3.17 %

Analyst ratings

FAQ

  • What is CNCR?
  • Does CNCR pay dividends?
  • What stocks are in CNCR?
  • What is the current assets under management for CNCR?
  • What is CNCR average volume?
  • What is CNCR expense ratio?
  • What is CNCR inception date?

What is CNCR?

The CNCR ETF is an exchange-traded fund that focuses on companies involved in cancer research and treatment. It aims to provide investors with exposure to the growing healthcare sector, particularly in oncology, by investing in firms developing innovative therapies and technologies for cancer care.

Does CNCR pay dividends?

Yes, the Range Cancer Therapeutics Index ETF does pays dividends, with the most recent payment being $1.85 per share. The last ex-dividend date was on December 29, 2021, and the next ex-dividend date has not been announced yet

What stocks are in CNCR?

As of today, Range Cancer Therapeutics Index ETF inlcudes 31 holdings, with 28 of them being companies from 8 different countries and 1 sectors. The most weighted holdings are Instil Bio (3.59%), Replimune (3.54%) and Iovance Biotherapeutics (3.47%)

What is the current assets under management for CNCR?

Assets under management of Range Cancer Therapeutics Index ETF is $13 M

What is CNCR average volume?

Average volume of Range Cancer Therapeutics Index ETF is $7482

What is CNCR expense ratio?

Expense ratio of Range Cancer Therapeutics Index ETF is 0.79%

What is CNCR inception date?

Inception date of Range Cancer Therapeutics Index ETF is October 14, 2015